Topics
May/June 2023 | Subfocus
Quantifying Fluid in AMD
Central subfoveal thickness isn’t the only biomarker clinicians can use to track disease progression and treatment effect.
Stela Vujosevic, MD, PhD, FARVO, FEBO
Clinical Trial Designs in Wet AMD: A Brief Review
Can newer therapies improve upon visual acuity and other outcomes for patients?
Carl D. Regillo, MD
The Effect of Biosimilars on Clinical Practice
A look at the true cost of the new drugs that are shaking up our therapeutic approaches.
Margaret M. Runner, MD, and George A. Williams, MD
April 17, 2026
Phase 1 Data for Vamikibart Published in JAMA Ophthalmology
MeiraGTx Announces the Acquisition of XLRP Therapy From J&J
April 16, 2026
Experimental Light-Activated Therapy Shows Early Promise for Retinitis Pigmentosa
April 15, 2026
Curative Biotechnology Engages Sterling Pharmaceutical Services to Manufacture Clinical Supply for Ophthalmic Program
April 2026 Insert
Editorially independent supported by Abbvie and Regenxbio
April 2026 Supplement
Editorially independent content supported with advertising by EyePoint
Free Print Subscription
Email Newsletter
Conference Calendar